We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
BeneTalk is an innovative digital therapeutic solution, providing on-demand support to individuals who stutter and their families, aiming to enhance their quality of life and confidence. Stuttering affects millions globally, and with limited specialized therapy options, BeneTalk addresses accessibility challenges by offering timely assistance, aiming to mitigate the higher risk of low self-esteem and mental health issues faced by individuals who stutter and their families.
days to go: Expired investment: £173,123
PayRue is a London based cryptocurrency wallet. It offers an application that enables people to exchange, store, and transfer cryptocurrency in a hassle freeway. PayRue has grown its user base over 22k registered users. Its application is live on Android, Web app, and iOS. PayRue is regulated for Digital Wallet services and Crypto exchange. It is offering exchange services of ETH, BTC, Propel, XLM, and USDC. The company is planning to allocate 40% of the invested funds for product development, 40% for marketing and 20% for admin.
days to go: Expired investment: £118,098
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Myn is an innovative source-to-pay platform driven by AI, aiming to establish a seamless network connecting companies, workers, and recruiters. Their end-to-end solution encompasses intelligent talent sourcing, self-service talent acquisition, fully funded payrolling services, digital compliance solutions, job boards, and enticing employee benefits.
days to go: Expired investment: £939,520
Similar to the functionality of workplace pensions, employees can invest part of their pay into an ISA and start to build a healthy saving habit. Smarterly's current clients include Rolls Royce, Samsung and OVO Energy and they have identified 85 other organisations with a collective 600,000 employees as potential opportunities. Due to the fundamentals of Smarterly being automated, there is no need to pay for a large staff and revenue is generated via small fees.
days to go: Expired investment: £1,638,150
Findr aims to automate the creation of business partnerships by providing easy access to hyper-targeted opportunities in minutes. The company asserts that its platform allows any business, regardless of its size, to sign up, post its partnership requirements, and explore opportunities for free. The company's portal allows users to request a 1-hour 'Discovery' call with a potential partner when the said user spots a relevant opportunity. Findr argues that it has made 'Discovery' for free for the first few months to build its user base. The company has onboarded 140 business users ranging from early-stage to global brands such as Mastercard, Uber and Visa since November 2020. Findr has featured in Forbes for helping businesses navigate COVID-19. The company will use the investment to develop two new price plans – Unlimited and Enterprise, introduce new platform features, hire a machine learning expert, and undertake digital activity to grow its user base.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £396,288
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph